
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is a clinical stage biopharmaceutical company with a promising pipeline of products in the fields of immunology, inflammation, and oncology, specifically its lead product Seralutinib. Key opinion leaders (KOLs) have shown support for the drug in relevant geographies and for moderate-to-high-risk patients, with management stating that physicians have shown particular interest in the approximately 26.5-meter and 25-30 meter placebo-adjusted benefits in North America and Europe, respectively. This geographic and physician support, coupled with the potential to address unmet needs in difficult-to-treat populations, makes Gossamer Bio's stock outlook positive for the foreseeable future.
Bears say
Gossamer Bio is facing several challenges that could negatively impact the company's future success. While the PROSERA CT FRI data provide some support for seralutinib's potential, it is not enough to outweigh the miss on the primary endpoint and issues with the high placebo response. In addition, the company is facing regulatory and commercial challenges, with the need for additional capital and a potential narrow patient population target for seralutinib. On top of that, Gossamer Bio also faces competition from both generic players and other established pharmaceutical companies.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares